SAN CARLOS, Calif., February 21, 2023 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. IOVAa late-stage biotechnology company developing novel T-cell-based cancer immunotherapies will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

To participate in the conference call, please register at https://register.event.com/register/BI103656b1b0f94a16a6e5f5c2886ad227. The live and archived web cast are available on the Investors section of the Company’s website, IR.Iovance.com. The archived webcast is available for one year.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics aims to be a global leader in the innovation, development and delivery of tumor infiltrating lymphocyte (TIL) cell therapies to cancer patients. We are pioneering a transformative approach to curing cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, Lifileucel for metastatic melanoma, has the potential to become the first approved single-cell therapy for a solid tumor cancer. The Iovance TIL platform has shown promising clinical data in several solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapies, that can extend and improve the lives of cancer patients. For more information, please visit www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” by Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company”, “we”, “us” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 ( the “PSLRA”). All statements, whether written or oral, made in this press release, other than statements of historical fact, are forward-looking statements…